Advertisement
CCXI vs IDYA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCXI is a Buy and IDYA is a Hold.
CCXI in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
CCXI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 9 of 9 cases where CCXI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CCXI's RSI Indicator exited the oversold zone, 8 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CCXI as a result. In 15 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for CCXI just turned positive on November 03, 2026. Looking at past instances where CCXI's MACD turned positive, the stock continued to rise in 6 of 8 cases over the following month. The odds of a continued upward trend are 75%.
Following a +21.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCXI advanced for three days, in 51 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCXI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for CCXI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. CCXI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.338) is normal, around the industry mean (-543.087). P/E Ratio (-5.958) is within average values for comparable stocks, (118.532). Projected Growth (PEG Ratio) (2.600) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. CCXI's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCXI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
IDYA's RSI Oscillator ascends from oversold territory
The RSI Oscillator for IDYA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 63 cases where IDYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on November 11, 2026. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 217 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 81 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.514) is normal, around the industry mean (3.498). P/E Ratio (-16.271) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CCXI | IDYA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 98 | 94 | |
PRICE GROWTH RATING 1..100 | 63 | 60 | |
P/E GROWTH RATING 1..100 | 20 | 30 | |
SEASONALITY SCORE 1..100 | 58 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (11) in the null industry is significantly better than the same rating for CCXI (97) in the Biotechnology industry. This means that IDYA’s stock grew significantly faster than CCXI’s over the last 12 months.
IDYA's Profit vs Risk Rating (80) in the null industry is in the same range as CCXI (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CCXI’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as CCXI (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CCXI’s over the last 12 months.
IDYA's Price Growth Rating (60) in the null industry is in the same range as CCXI (63) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CCXI’s over the last 12 months.
CCXI's P/E Growth Rating (20) in the Biotechnology industry is in the same range as IDYA (30) in the null industry. This means that CCXI’s stock grew similarly to IDYA’s over the last 12 months.
| CCXI | IDYA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 1 day ago 90% |
| Stochastic ODDS (%) | 2 days ago 56% | 1 day ago 73% |
| Momentum ODDS (%) | 2 days ago 63% | 1 day ago 75% |
| MACD ODDS (%) | 2 days ago 75% | 1 day ago 83% |
| TrendWeek ODDS (%) | 2 days ago 47% | 1 day ago 77% |
| TrendMonth ODDS (%) | 2 days ago 39% | 1 day ago 85% |
| Advances ODDS (%) | 8 days ago 65% | 3 days ago 75% |
| Declines ODDS (%) | 13 days ago 82% | 9 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 90% | 1 day ago 81% |
| Aroon ODDS (%) | 2 days ago 82% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CCXI’s FA Score shows that 1 FA rating(s) are green while IDYA’s FA Score has 2 green FA rating(s).
- CCXI’s FA Score: 1 green, 4 red.
- IDYA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CCXI’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).
- CCXI’s TA Score: 5 bullish, 3 bearish.
- IDYA’s TA Score: 4 bullish, 5 bearish.
Price Growth
CCXI (@Financial Conglomerates) experienced а +5.33% price change this week, while IDYA (@Biotechnology) price change was +1.34% for the same time period.
The average weekly price growth across all stocks in the @Financial Conglomerates industry was +0.30%. For the same industry, the average monthly price growth was +0.14%, and the average quarterly price growth was +1.92%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
IDYA is expected to report earnings on Feb 23, 2027.
Industries' Descriptions
@Financial Conglomerates (+0.30% weekly)Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CCXI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CCXI has been loosely correlated with SPRO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CCXI jumps, then SPRO could also see price increases.
| Ticker / NAME | Correlation To CCXI | 1D Price Change % | ||
|---|---|---|---|---|
| CCXI | 100% | N/A | ||
| SPRO - CCXI | 48% Loosely correlated | -5.61% | ||
| ABOS - CCXI | 48% Loosely correlated | -2.95% | ||
| ANVS - CCXI | 34% Loosely correlated | -3.00% | ||
| IPHA - CCXI | 34% Loosely correlated | +1.33% | ||
| IDYA - CCXI | 34% Loosely correlated | -0.87% | ||
More | ||||
IDYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with RNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To IDYA | 1D Price Change % | ||
|---|---|---|---|---|
| IDYA | 100% | +3.04% | ||
| RNA - IDYA | 48% Loosely correlated | -3.28% | ||
| SLDB - IDYA | 47% Loosely correlated | +6.00% | ||
| EDIT - IDYA | 45% Loosely correlated | -4.99% | ||
| DYN - IDYA | 44% Loosely correlated | +0.39% | ||
| MGTX - IDYA | 44% Loosely correlated | +0.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AGEM | 45.55 | 1.17 | +2.63% |
| abrdn Emerging Markets Dividend Active ETF (AGEM) | |||
| LDRH | 23.96 | 0.01 | +0.04% |
| iShares iBonds 1-5 Year High Yield and Income Ladder ETF | |||
| QQQX | 30.68 | N/A | N/A |
| Nuveen NASDAQ 100 Dynamic Overwrite Fund | |||
| FLSW | 44.69 | -0.36 | -0.80% |
| Franklin FTSE Switzerland ETF (FLSW) | |||
| CGRO | 16.35 | -0.27 | -1.61% |
| CoreValues Alpha Greater China Growth ETF (CGRO) | |||